ライフサイエンスコーパス: human immunodeficiency virus 1

1 tiple cell types and can be a coreceptor for human immunodeficiency virus 1.

2 cytes (CTLs) can undermine immune control of human immunodeficiency virus 1.

3 eceptor for infection by T-tropic strains of human immunodeficiency virus-1.

4 se, no CNS involvement, and no antibodies to human immunodeficiency virus-1.

5 ffinity antibodies, and APOBEC3G inactivates human immunodeficiency virus-1.

6 m 200 United States blood donors and from 58 human immunodeficiency virus-1, 18 human immunodeficienc

7 ay, and none of 2,831 were positive for both human immunodeficiency virus 1/2 and hepatitis B surface

8 By contrast, the human immunodeficiency virus 1 activator Tat, which is r

9 immunity is associated with control of both human immunodeficiency virus-1 and HCV suggests a common

10 inhibitors in an individual coinfected with human immunodeficiency virus-1 and HCV.

11 small animal model for the in vivo study of human immunodeficiency virus-1 and other fastidious infe

12 cessing of gp160 may be useful for combating human immunodeficiency virus-1 and that polyarginine rep

13 oma in an elderly woman who was negative for human immunodeficiency viruses 1 and 2, and hepatitis B

14 d for budding of enveloped viruses including human immunodeficiency virus 1, and for membrane absciss

15 rophic lateral sclerosis, Alzheimer disease, human immunodeficiency virus 1-associated dementia, and

16 Patients with human immunodeficiency virus 1-associated immunological

17 on of multiple biotargets including viruses (Human Immunodeficiency Virus-1), bacteria (Escherichia c

18 In contrast, IST1 depletion did not inhibit human immunodeficiency virus-1 budding.

19 neous control of hepatitis C virus (HCV) and human immunodeficiency virus-1, but for HCV the roles of

20 cavity mediates a weak association with the human immunodeficiency virus-1 capsid protein, supportin

21 Worldwide, the majority of human immunodeficiency virus-1 cases occur through heter

22 the bacterial toxin lipopolysaccharide, the human immunodeficiency virus-1 coat protein glycoprotein

23 for the purpose of specific cleavage of the human immunodeficiency virus-1 coat protein gp120.

24 molecular adaptation rates from 24 published human immunodeficiency virus 1 coding data sets.

25 The homodimeric protease of the human immunodeficiency virus 1 contains two cysteine res

26 is for understanding the mechanism of mature human immunodeficiency virus-1 core assembly and avenues

27 During the morphogenesis of mature human immunodeficiency virus-1 cores, viral capsid prote

28 hese data suggest that mutations in dominant human immunodeficiency virus 1 CTL epitopes may accumula

29 efficient gene transfer is obtained using a human immunodeficiency virus-1-derived lentiviral vector

30 Integrase-deficient human immunodeficiency virus-1-derived vectors provide a

31 ian retrovirus frameshifting element and the Human immunodeficiency virus-1 dimerization kissing hair

32 een found to be a key cellular component for human immunodeficiency virus-1, Ebola, Marburg, and meas

33 Human immunodeficiency virus-1 employs strand transfer f

34 ocyte migration across BBB in the setting of human immunodeficiency virus-1 encephalitis (HIVE).

35 Neuroinflammatory disorders (including human immunodeficiency virus-1 encephalitis, HIVE) are a

36 Mechanisms underlying human immunodeficiency virus-1 encephalopathy are not co

37 HIV (human immunodeficiency virus)-1 Env is displayed on the

38 This processing of human immunodeficiency virus-1 envelope protein, gp160,

39 ypothetical models were used to describe the human immunodeficiency virus 1 epidemic (epidemic hetero

40 10(-12)M is achievable for the detection of human immunodeficiency virus 1 gene with a detection lim

41 eus, inhibit anthrax lethal factor, and bind human immunodeficiency virus-1 gp120.

42 er, we verified that authentic processing of human immunodeficiency virus-1 gp160 synthesized in huma

43 and 19, herpes simplex virus (HSV) 1 and 2, human immunodeficiency virus 1, hepatitis C virus, enter

44 Human immunodeficiency virus 1 (HIV) buds via lipid raft

45 he cell-penetrating peptide derived from the human immunodeficiency virus 1 (HIV) transactivator prot

46 of ARC fused with the transduction domain of human immunodeficiency virus 1 (HIV-1) (TAT-ARC) on Fas-

47 d nucleosome remodeling with a region of the human immunodeficiency virus 1 (HIV-1) 5' long terminal

48 ne is to generate immunity that will prevent human immunodeficiency virus 1 (HIV-1) acquisition.

49 e Vif (virion infectivity factor) protein of human immunodeficiency virus 1 (HIV-1) acts by overcomin

50 Virions of wild-type human immunodeficiency virus 1 (HIV-1) and a mutant simi

51 Maternal virus load of human immunodeficiency virus 1 (HIV-1) and maternal immu

52 The proline-rich L domains of human immunodeficiency virus 1 (HIV-1) and other retrovi

53 e receptor 5 (CCR5), the major coreceptor of human immunodeficiency virus 1 (HIV-1) and simian immuno

54 The capsid protein (CA) of human immunodeficiency virus 1 (HIV-1) assembles into a

55 l dissemination within an infected host, and human immunodeficiency virus 1 (HIV-1) can exploit this

56 nal mononuclear cells in the pathogenesis of human immunodeficiency virus 1 (HIV-1) disease has not b

57 Human immunodeficiency virus 1 (HIV-1) fails to transduc

58 c and phenotypic susceptibility of subtype C human immunodeficiency virus 1 (HIV-1) following first-l

59 The eradication of human immunodeficiency virus 1 (HIV-1) from infected per

60 al activator which is required for efficient human immunodeficiency virus 1 (HIV-1) gene expression T

61 resistance mutations in enzymatic targets of human immunodeficiency virus 1 (HIV-1) hampers the abili

62 SAMHD1 is a host restriction factor for human immunodeficiency virus 1 (HIV-1) in cultured human

63 Differentiating individuals with early human immunodeficiency virus 1 (HIV-1) infection from th

64 espread use of antiretroviral drugs to treat human immunodeficiency virus 1 (HIV-1) infection may res

65 Human immunodeficiency virus 1 (HIV-1) infection may res

66 Little is known about whether human immunodeficiency virus 1 (HIV-1) infection of leuk

67 re standard of care for initial treatment of human immunodeficiency virus 1 (HIV-1) infection, but a

68 Persons at risk of human immunodeficiency virus 1 (HIV-1) infection, have b

69 gh there has been great progress in treating human immunodeficiency virus 1 (HIV-1) infection, preven

70 CXCR4 are the major coreceptors that mediate human immunodeficiency virus 1 (HIV-1) infection, while

71 The human immunodeficiency virus 1 (HIV-1) is a complex retr

72 The mechanism of human immunodeficiency virus 1 (HIV-1) minus strand tran

73 Human immunodeficiency virus 1 (HIV-1) Nef downregulates

74 rent proteins to bind various regions of the human immunodeficiency virus 1 (HIV-1) promoter.

75 The human immunodeficiency virus 1 (HIV-1) protease (PR) is

76 ells, and inhibits fusion and infectivity of human immunodeficiency virus 1 (HIV-1) R5 viruses by co-

77 Although host defense against human immunodeficiency virus 1 (HIV-1) relies mainly on

78 Infection with human immunodeficiency virus 1 (HIV-1) results in the di

79 During and after minus-strand DNA synthesis, human immunodeficiency virus 1 (HIV-1) reverse transcrip

80 Sex-based differences in the levels of human immunodeficiency virus 1 (HIV-1) RNA in plasma cou

81 Ab combination assay (index test) and pooled human immunodeficiency virus 1 (HIV-1) RNA testing.

82 envelop glycoprotein from the T-cell-tropic human immunodeficiency virus 1 (HIV-1) strain IIIB is a

83 In human glial cells, the human immunodeficiency virus 1 (HIV-1) Tat protein activ

84 The human immunodeficiency virus 1 (HIV-1) viral protein R (

85 DCs at body surfaces can capture human immunodeficiency virus 1 (HIV-1), but mature DCs d

86 types exist for three major viral pathogens: human immunodeficiency virus 1 (HIV-1), hepatitis C viru

87 rus replication in individuals infected with human immunodeficiency virus 1 (HIV-1), little is known

88 CD4 molecules are the primary receptors for human immunodeficiency virus 1 (HIV-1), we conclude that

89 V are worse in those who are coinfected with human immunodeficiency virus 1 (HIV-1), which is unfortu

90 athogenetic and neurologic similarities with human immunodeficiency virus 1 (HIV-1)-associated neuroc

91 Human immunodeficiency virus 1 (HIV-1)-infected (n=1763)

92 varicella-zoster vaccine are recommended for human immunodeficiency virus 1 (HIV-1)-infected children

93 ics plays in the modification of the rate of human immunodeficiency virus 1 (HIV-1)-related disease p

94 rion infectivity factor deficient (Deltavif) human immunodeficiency virus 1 (HIV-1).

95 s-activation response element (TAR RNA) from human immunodeficiency virus 1 (HIV-1).

96 as a risk factor in the transmission of the human immunodeficiency virus 1 (HIV-1).

97 gates the production of retroviruses such as human immunodeficiency virus 1 (HIV-1).

98 test mechanisms of minus strand transfer of human immunodeficiency virus 1 (HIV-1).

99 Coinfection with human immunodeficiency virus-1 (HIV) and hepatitis B vir

100 ssing simian immunodeficiency virus (SIV) or human immunodeficiency virus-1 (HIV) envelope (gp130 and

101 Human immunodeficiency virus-1 (HIV) targets the monocyt

102 Postnatal transmission of human immunodeficiency virus-1 (HIV) via breastfeeding r

103 Retroviruses, such as human immunodeficiency virus-1 (HIV), integrate their ge

104 play a key role in the neuropathogenesis of Human Immunodeficiency Virus-1 (HIV)4 associated dementi

105 the two major pathogenic human retroviruses, human immunodeficiency virus-1 (HIV-1) and human T-lymph

106 s been hindered by the enormous diversity of human immunodeficiency virus-1 (HIV-1) and its ability t

107 We explored the effects of human immunodeficiency virus-1 (HIV-1) and its Tat trans

108 Human immunodeficiency virus-1 (HIV-1) antagonizes BST2

109 During human immunodeficiency virus-1 (HIV-1) assembly, the hos

110 or signaling and the in vitro replication of human immunodeficiency virus-1 (HIV-1) at concentrations

111 DC-SIGN is also a unique type of human immunodeficiency virus-1 (HIV-1) attachment factor

112 ted that the surface glycoprotein (gp120) of human immunodeficiency virus-1 (HIV-1) can induce damage

113 Human immunodeficiency virus-1 (HIV-1) can induce dement

114 Human antibodies to human immunodeficiency virus-1 (HIV-1) can neutralize a

115 antibodies is a major limitation of current human immunodeficiency virus-1 (HIV-1) candidate vaccine

116 The mature human immunodeficiency virus-1 (HIV-1) capsid is best de

117 terminal domain, residues 146 to 231, of the human immunodeficiency virus-1 (HIV-1) capsid protein [C

118 Infection with human immunodeficiency virus-1 (HIV-1) causes brain inju

119 cells with genes that inhibit replication of human immunodeficiency virus-1 (HIV-1) could lead to dev

120 Many patients infected with human immunodeficiency virus-1 (HIV-1) develop a syndrom

121 After host entry through mucosal surfaces, human immunodeficiency virus-1 (HIV-1) disseminates to l

122 otective mechanisms in laboratory and murine human immunodeficiency virus-1 (HIV-1) encephalitis (HIV

123 The issue of how human immunodeficiency virus-1 (HIV-1) enters the body f

124 The human immunodeficiency virus-1 (HIV-1) envelope glycopro

125 Perispinal (intrathecal) injection of the human immunodeficiency virus-1 (HIV-1) envelope glycopro

126 The Human Immunodeficiency Virus-1 (HIV-1) envelope glycopro

127 on between cell pairs consisting of a single human immunodeficiency virus-1 (HIV-1) envelope glycopro

128 The human immunodeficiency virus-1 (HIV-1) envelope glycopro

129 Human immunodeficiency virus-1 (HIV-1) envelope protein

130 he transactivator protein Tat encoded by the human immunodeficiency virus-1 (HIV-1) genome reduces gl

131 rved following treatment of neurons with the human immunodeficiency virus-1 (HIV-1) glycoprotein gp12

132 ibody b12 recognizes the CD4-binding site of human immunodeficiency virus-1 (HIV-1) gp120 and is one

133 Variable regions 1 and 2 (V1/V2) of human immunodeficiency virus-1 (HIV-1) gp120 envelope gl

134 Human immunodeficiency virus-1 (HIV-1) has evolved a cun

135 Human immunodeficiency virus-1 (HIV-1) has infected more

136 The Nef protein of human immunodeficiency virus-1 (HIV-1) has previously be

137 The design of a human immunodeficiency virus-1 (HIV-1) immunogen that ca

138 n of the genetically modified cells into the human immunodeficiency virus-1 (HIV-1) infected donor, h

139 A small proportion of human immunodeficiency virus-1 (HIV-1) infected individu

140 Human immunodeficiency virus-1 (HIV-1) infection current

141 Human immunodeficiency virus-1 (HIV-1) infection decreas

142 Although many mechanisms by which human immunodeficiency virus-1 (HIV-1) infection eventua

143 al agents that can reduce the enhancement of human immunodeficiency virus-1 (HIV-1) infection in cell

144 matopoietic progenitor cells are affected by human immunodeficiency virus-1 (HIV-1) infection in vivo

145 Human immunodeficiency virus-1 (HIV-1) infection is asso

146 Prolonged human immunodeficiency virus-1 (HIV-1) infection leads t

147 melanoma cells, resistance or sensitivity to human immunodeficiency virus-1 (HIV-1) infection of huma

148 Human immunodeficiency virus-1 (HIV-1) infection of the

149 Patients with human immunodeficiency virus-1 (HIV-1) infection often p

150 By destroying CD4+ T cells, human immunodeficiency virus-1 (HIV-1) infection results

151 During the first weeks of human immunodeficiency virus-1 (HIV-1) infection, cytoto

152 nd chemokine receptors modify progression of human immunodeficiency virus-1 (HIV-1) infection.

153 se III clinical testing for the treatment of human immunodeficiency virus-1 (HIV-1) infection.

154 t are key regulators of the host response to human immunodeficiency virus-1 (HIV-1) infection.

155 lvement is a well-documented complication of human immunodeficiency virus-1 (HIV-1) infection.

156 al transmission accounts for the majority of human immunodeficiency virus-1 (HIV-1) infections worldw

157 arly simian immunodeficiency virus (SIV) and human immunodeficiency virus-1 (HIV-1) infections, gut-a

158 The human immunodeficiency virus-1 (HIV-1) infects helper CD

159 Although human immunodeficiency virus-1 (HIV-1) infects quiescent

160 We have previously shown that human immunodeficiency virus-1 (HIV-1) integrase is an u

161 e catalyzed by retroviral integrases such as human immunodeficiency virus-1 (HIV-1) integrase.

162 udy, 903 murine leukemia virus (MLV) and 379 human immunodeficiency virus-1 (HIV-1) integrations in t

163 hat plays a central role in the entry of the human immunodeficiency virus-1 (HIV-1) into immune cells

164 Reverse transcriptase (RT) of human immunodeficiency virus-1 (HIV-1) is a multifunctio

165 The Nef protein of human immunodeficiency virus-1 (HIV-1) is essential for

166 Human immunodeficiency virus-1 (HIV-1) is usually transm

167 orming comparative proteomics of established human immunodeficiency virus-1 (HIV-1) latent cell model

168 Human immunodeficiency virus-1 (HIV-1) may utilize autop

169 ynthesized in human cells from an infectious human immunodeficiency virus-1 (HIV-1) molecular clone w

170 ility leukocyte antigens (HLA)-B8-restricted human immunodeficiency virus-1 (HIV-1) nef epitope, FLKE

171 To characterize the effect of human immunodeficiency virus-1 (HIV-1) nef expression in

172 Direct killing of CD4+ lymphocytes by human immunodeficiency virus-1 (HIV-1) probably cannot a

173 Previous genetic association studies of human immunodeficiency virus-1 (HIV-1) progression have

174 experimental protocol for folding the mature human immunodeficiency virus-1 (HIV-1) protease is prese

175 The ability of human immunodeficiency virus-1 (HIV-1) protease to devel

176 cytotoxic T lymphocytes (CTLs) in containing human immunodeficiency virus-1 (HIV-1) replication in in

177 cellular immunity is involved in controlling human immunodeficiency virus-1 (HIV-1) replication.

178 gene Mg11, has recently been identified as a human immunodeficiency virus-1 (HIV-1) restriction facto

179 seek potential non-nucleoside inhibitors of human immunodeficiency virus-1 (HIV-1) reverse transcrip

180 high-throughput screening for inhibitors of human immunodeficiency virus-1 (HIV-1) reverse transcrip

181 The relationship of serum human immunodeficiency virus-1 (HIV-1) RNA levels to HIV

182 s a determinant in the V3 loop of gp120 from human immunodeficiency virus-1 (HIV-1) SF2, and MAb 26.2

183 e elongation when directed to an intron-free human immunodeficiency virus-1 (HIV-1) template.

184 XCR4 is also a major receptor for strains of human immunodeficiency virus-1 (HIV-1) that arise during

185 The ability of human immunodeficiency virus-1 (HIV-1) to undergo effici

186 We have recently reported that human immunodeficiency virus-1 (HIV-1) transcription is

187 y, progress in ex vivo gene therapy (GT) for human immunodeficiency virus-1 (HIV-1) treatment has bee

188 munizations with glycoprotein 120 (gp120) of human immunodeficiency virus-1 (HIV-1) usually require b

189 A global human immunodeficiency virus-1 (HIV-1) vaccine will have

190 Current human immunodeficiency virus-1 (HIV-1) vaccines elicit s

191 Human immunodeficiency virus-1 (HIV-1) Vif is essential

192 Human immunodeficiency virus-1 (HIV-1) Vif overcomes the

193 sphingolipid incorporated in the membrane of human immunodeficiency virus-1 (HIV-1) viral particles,

194 Human immunodeficiency virus-1 (HIV-1) Vpr expression ha

195 a-L) and lymphotropic (A018-post) strains of human immunodeficiency virus-1 (HIV-1) was examined.

196 he preferential infection and replication of human immunodeficiency virus-1 (HIV-1) within naive (CD4

197 A deaminase that inhibits the replication of human immunodeficiency virus-1 (HIV-1), other retrovirus

198 , may themselves be infected by viruses like human immunodeficiency virus-1 (HIV-1), which impair the

199 beta) is characteristic for normal aging and human immunodeficiency virus-1 (HIV-1)-associated altera

200 n many neurodegenerative diseases, including human immunodeficiency virus-1 (HIV-1)-associated neuroc

201 IV-1 genes" into hematopoietic stem cells of human immunodeficiency virus-1 (HIV-1)-infected individu

202 n attempt to restore immune competence to 12 human immunodeficiency virus-1 (HIV-1)-infected patients

203 hly active antiretroviral therapy, globally, human immunodeficiency virus-1 (HIV-1)-positive patients

204 gene encoding CCL3L1 (MIP-1alphaP), a potent human immunodeficiency virus-1 (HIV-1)-suppressive chemo

205 imate immunodeficiency viruses, most notably human immunodeficiency virus-1 (HIV-1).

206 cation device for the rapid diagnosis of the human immunodeficiency virus-1 (HIV-1).

207 ay or once per day to subjects infected with human immunodeficiency virus-1 (HIV-1).

208 The development of the human immunodeficiency virus-1 (HIV-1)/simian immunodefi

209 hat bind the reverse transcriptase enzyme of human immunodeficiency virus-1 (HIV-RT) in an expanded v

210 (NF-kappaB)-dependent promoter (from the 5' human immunodeficiency virus-1 [HIV-1] long terminal rep

211 infection with the T-lymphotropic strain of human immunodeficiency virus-1, HIV-1IIIB.

212 Rare human immunodeficiency virus 1-infected individuals, ter

213 Human immunodeficiency virus 1 infection was used as an

214 al pathological conditions including sepsis, human immunodeficiency virus 1 infection, and cancer.

215 erse collection of human diseases, including human immunodeficiency virus-1 infection, acute myeloid

216 d NK activity has been shown to protect from human immunodeficiency virus-1 infection.

217 ed polyarginine for inhibition of productive human immunodeficiency virus-1-infection in T-cell lines

218 sue of Immunity, Blanchet et al. report that human immunodeficiency virus-1 inhibits macroautophagy i

219 lytic core domain is similar to the folds of human immunodeficiency virus-1 integrase, avian sarcoma

220 ntegration sites for avian sarcoma virus and human immunodeficiency virus-1 integrases within the ste

221 K1 activator, induced transcription from the human immunodeficiency virus-1 long terminal repeat and

222 Thus, human immunodeficiency virus 1 may evade protective T ce

223 eliberate redirection of T cell responses to human immunodeficiency virus-1 might enhance immunity an

224 tudy, we simulated the membrane anchoring of human immunodeficiency virus-1 myristoylated MA protein

225 d in the presence of an SH3-binding protein (human immunodeficiency virus-1 Nef), indicating persiste

226 igible if they were previously untreated and human immunodeficiency virus-1 negative, had biopsy-prov

227 on datasets from 140 sequenced samples from human immunodeficiency virus-1 or influenza-virus-infect

228 e-strand DNA and inhibits the replication of human immunodeficiency virus-1, other retroviruses, and

229 with the neoAgs keyhole limpet hemocyanin or human immunodeficiency virus-1 p24 gag prior to TNF-alph

230 velopment, including cardiac hypertrophy and human immunodeficiency virus-1 pathogenesis.

231 ignment of the Ty3 retrotransposon RT on the human immunodeficiency virus-1 PPT induces imprecise rem

232 ach attempts to genetically engineer an HIV (human immunodeficiency virus)-1 protease that is functio

233 sing computer-generated conformations of apo human immunodeficiency virus-1 protease (HIV-1p).

234 the success of the method by applying it to human immunodeficiency virus-1 protease (HIV-1p).

235 determination of structural determinants of human immunodeficiency virus-1 protease specificity.

236 e factor (Nef) protein, an immunosuppressive human immunodeficiency virus 1 protein expressed and rel

237 ed with ACE2, but not those transfected with human immunodeficiency virus-1 receptors, formed multinu

238 The co-packaged RNA genomes of human immunodeficiency virus-1 recombine at a high rate.

239 nd that polyarginine inhibited significantly human immunodeficiency virus-1 replication at concentrat

240 By use of the human immunodeficiency virus-1 Rev complementation assay

241 The kinetics of interaction between the human immunodeficiency virus-1 Rev protein and its RNA t

242 espite the key role played by the RNase H of human immunodeficiency virus-1 reverse transcriptase (HI

243 ytidine (ddCTP), on DNA strand elongation by human immunodeficiency virus-1 reverse transcriptase (HI

244 Human immunodeficiency virus-1 reverse transcriptase (RT

245 9,10-epoxide (BPDE) on translesion bypass by human immunodeficiency virus-1 reverse transcriptase and

246 of the replication pattern between wild type human immunodeficiency virus-1 reverse transcriptase and

247 istics Homology of the HBV polymerase to the human immunodeficiency virus-1 reverse transcriptase has

248 ch as bacteriophage T7(-) DNA polymerase and human immunodeficiency virus-1 reverse transcriptase in

249 atomic force microscope, motor forces of the human immunodeficiency virus-1 reverse transcriptase wer

250 HIV-1 RT (human immunodeficiency virus-1 reverse transcriptase) is

251 steady-state kinetic studies using wild-type human immunodeficiency virus-1 RT and two substitution m

252 ate that residues conserved between TERT and human immunodeficiency virus-1 RT are more likely than T

253 We have investigated the role that human immunodeficiency virus-1 RT residues in the alphaH

254 rom the structural alignment of RT-Ec86 with human immunodeficiency virus-1 RT.

255 Human immunodeficiency virus-1 subtypes A and C differ i

256 s with a sequence-specific DNA probe for the human immunodeficiency virus 1 system on nitrocellulose

257 Human immunodeficiency virus-1 tat (HIV-tat) protein, li

258 oriens did not migrate extensively, whereas human immunodeficiency virus-1 tat-activated microglia m

259 ion of ABAD-DP [fused to the transduction of human immunodeficiency virus 1-transactivator (Tat) prot

260 small animal in vivo system for the study of human immunodeficiency virus-1 transmission and infectio

261 In the context of HIV-1 (human immunodeficiency virus-1) transmission, Langerhans

262 Single-dose nevirapine reduces intrapartum human immunodeficiency virus 1 type (HIV-1) transmission

263 uences, Mal and Lai, have been found in most human immunodeficiency virus 1 variants.

264 that, when activated by hydroxyurea, UV, or human immunodeficiency virus-1 Vpr, causes cell cycle ar

265 hk1 phosphorylation when ATR is activated by human immunodeficiency virus-1 Vpr.

266 The minus strand transfer mechanism in human immunodeficiency virus-1 was examined in vitro wit

267 iruses human-T cell lymphotropic virus I and human immunodeficiency virus 1, we used an alpha-amaniti

268 d-generation lentiviral vectors derived from human immunodeficiency virus 1 were evaluated, with the

269 sed on the overall data, we conclude that in human immunodeficiency virus-1, which contains a 97-nt R

270 Individuals infected with human immunodeficiency virus-1 who abuse opiates can hav